Menu Close

22 Senior Speakers Including Roche, Bupa, Ipsen, Merck & Pfizer Take To The Stage In 1 Day At The Patient Centricity & Engagement Conference

Secure Better Patient & Business Outcomes With Actionable, Tangible, Value-Adding Strategies To Enhance Patient Centricity & Engagement & Embed Patients At The Heart Of Decision Making
Collaborative Engagement & Experience Strategies Which Inform Clinical Trial Design, Drug Development & Strategic Business Direction With Early Patient Involvement, Insights & Feedback, Leverage Digital & Technology Innovations Compliantly & Enhance Patient Safety & Journey. A One-Day Conference & Networking Event, 21st May 2019, The Hallam Conference Centre, Central London

08:30 Registration, Morning Coffee & Objective Setting

09:00 GIC Welcome & Morning Chair’s Opening Remarks

Okan Ekinci
Chief Medical Officer



09.15 Truly Embedding Patient Centricity Into Business Decision Making With Meaningful Patient Involvement For Tangibly Enriched Patient & Business Outcomes

  • Recognising the gaps between intent and action: taking a good look at internal strategies to determine where increased patient input can make the most impact on patient outcomes and commercial success; bring the patient voice into the organisation
  • Demonstrating a financial payoff to further motivate internal departments to involve patients in decision making and convince them of the importance of patient-pharma collaboration
  • How can we overcome industry hurdles such as tight regulations, communications barriers and internal apathy to deliver real examples of commitment, change and tangible outputs as well as a commitment to progress and more meaningful patient involvement?

Jeffrey Wren
Executive Vice President, Neurology Patient Value Head


09.35 Clinical Trial Design & Drug Development: Recruit & Action Patient Feedback On Trial Design For More Effective R&D & Better Patient Outcomes & Experiences

  • Innovative methods of creating awareness and recruiting patients into early-stage R&D for crucial patient feedback which improves trial experience and effectiveness
  • Bridging the gap between patients, industry and stakeholder insights and needs and real-world evidence for meaningful, multi-stakeholder drug development processes
  • Practical steps to feed patient-reported outcomes and insights into development strategies which build patient value into design
  • Closing the loop – how can pharma brands build a community and better relay the outcomes of a clinical trial to the patient volunteers?
vertical new

09.35 Perspective One:

Jeffrey Wren
Executive Vice President, Neurology Patient Value Head

09.55 Perspective Two:

David Rich
Vice President, Clinical Development, Rare Diseases, Global R&D


10.15 The Patient Perspective: What Can Pharma Do To Enable More Meaningful & Effective Patient-Pharma Collaboration?

  • Pharma want to know how they can better create awareness, engage patients and feed patient feedback into the decision making of the company. What do you think they should be doing differently?
  • The patient point of view – what in the system do you want to challenge and what do you and the patient community expect from the pharma industry?
  • The future: how do you think long-term pharma-patient relationships could be improved? What measures would you like to see put in place?

Alison Doyle
Clinical & Operations Director
National Osteoporosis Society

Sara Osborne
Head of Patient Communication & Involvement
Cancer Research

Further panellists to be announced. Please check the website for updates.

Simon Nicholls
Global Product Director (Customer Labs)

10.45 Morning Refreshment Break With Informal Networking

Breakout Groups By Therapy Area:

A: Cancer Care
B: Mental Health
C: Long-Term Conditions
D: Rare Diseases
E: Diabetes
F: Other Breakouts By Area


11.15 Our Story: Real-Life Patient-Pharma Collaboration – Overcoming Barriers For Meaningful, Value-Adding Relationships Which Positively Impact Patient Outcomes & Pharma’s Bottom Line

  • How our relationship started: from initial contact to long-term partnership, how did our relationship evolve and what helped it flourish?
  • How did we enable this collaboration to be effective? What did we both need and how did we overcome hurdles and manage expectations to align our shared objectives?
  • Who else did we need? From third parties, regulatory boards and HCPs, how did we motivate and involve the right people?
  • What have we achieved? Evidence of value created for patients, the healthcare system and pharma

Vanessa Pott
Director, Patient Advocacy & Strategic Partnerships


PLUS! Patient Partner Speaker To Be Confirmed

11.35 Bonus Session Reserved For Exclusive Conference Partner. For more information on how to get involved, please call +44 (0) 20 3479 2299 or email


12.05 Exploring Blockers To Multi-Stakeholder Collaboration: How Can We All Align Behind The Patient?

There are many reasons why it can be difficult to have meaningful patient input within pharma. This panel is bringing together key stakeholders within the industry to explore how multi-stakeholder collaboration can be approached more efficiently to uncover tangible ways of moving forwards together.

Liesbeth De Boer-Oosterhuis
Manager Alliance Development & Patient Advocacy


Jill Pearcy
ABPI Code Engagement

Further speakers to be announced. Please check the website for further details.

12.35 Lunch For Speakers, Delegates & Partners

13.05 Informal Peer-To-Peer Discussion Zones

A) Patient Experience

Dr Mate A. Balazs
Country Head - Patient Safety

B) Clinical Trials

Dr Helen Bulbeck
Director of Services & Policy

Brainstrust - the brain cancer people

Stephen Nabarro
Head of Clinical Operations & Data Management, Centre for Drug Discovery

Cancer Research


D) Patient Recruitment

13.35 Afternoon Chair’s Opening Remarks

Paul Edwards
Director of Clinical Services
Dementia UK


13.50 Challenges In Providing Accurate Information To Patients, With An Insight Into Data Use

  • How are patients seeking information? What tools are out there today to handle patient data and information to provide the best possible experiences?
  • Innovative and effective methodologies to collect accurate patient data and translate patient feedback and data into actionable insights to improve patient services
  • What should change to significantly improve the value and quality of clear information to patients?

Krzysztof Wojciechowski
Public Policy & Patient Engagement Director, Europe, Russia, Africa, Middle East


14.10 Leveraging New Technologies Compliantly To Improve Patient Experience For Interactive Communications Which Engage Patients Around Their Healthcare

  • Exploring the potential impact and long-term implications of new technologies on patient care: what are the innovations we need to sit up and listen to, what do patients want and how can we make a real difference with quite simple tech and tools?
  • Applying digital channels and technologies to enhance patient recruitment, increase patient engagement through clinical trials and accessing information about their treatment
  • Identifying opportunities new tech offers to collect valuable and intangible data such as emotions, reactions side effects, adverse event reporting and ineffective drugs during trials and with drugs on the market
  • Exploring the implications of the HTA reform

14:10 Perspective One

Nathalia Figueiredo
Consumer Planning & Insights
Walgreens Boots Alliance

14:30 Perspective Two

Isabel Torres
VP Market Access, Public A airs & Patient Advocacy, Europe & Canada


14.55 Bonus Session Reserved For Exclusive Conference Partner. For more information on how to get involved, please call +44 (0) 20 3479 2299 or email

15.25 Afternoon Refreshment Break With Informal Networking


15.50 Determining The Impact Of Patient-Pharma Collaboration & Value Added To The Patient & The Business

  • How do you tangibly measure value-added? How do you measure how valuable and effective patient engagement is?
  • Patient reported outcomes - what do patients consider value adding?
  • Creating value is great – but, how can you create value at scale?

Geoff Rollason
Patient Experience & Service Director


16.10 Significant Measures Pharma Can Take To Further Ensure Patient Safety Throughout The Patient Journey

  • Ensuring it is patient safety at the forefront of decision making
  • Refining your patient safety strategies in the real world where increased complexities, comorbidities and other drugs ramp up the chances of an adverse reaction
  • Better engaging and communicating with the patient around their treatment by using technologies to educate them on reporting and their own conditions
  • Understanding and consulting on patient preference and going beyond patient experience to decide risk-reward profiles

16.10 Perspective One
James Whitehead

Principal, Pharmacovigilance Processes & Partnerships


16.50 It’s All Very Well Talking The Talk But How Can Pharma Actually Take Steps To Progress Their Patient Strategies, Improve Patient Outcomes & Further The Business?

How can you overcome barriers to:

  • Health-check your own activities and ensure your organisation is really patient-centric - then readdress strategies if necessary?
  • Adapt to different patient behaviours, engagement and motivation levels?
  • Enhance patient communications and engage better with the patient on decision making?
  • Successfully execute initiatives in view of regulation?

Sara Osborne
Head of Patient Communication & Involvement
Cancer Research

Paul Robinson
European Lead, Patient Innovation


Isabela Niculae
Associate Director Global Patient Recruitment & Retention Strategist


Heather Moses
Head of Medical Affairs Oncology


17.00 Co-Chairs’ Closing Remarks & Official Close Of Conference